On 30 September 2020, the results of the rapid collaborative review “Remdesivir for the treatment of COVID-19. PICO and evidence gaps” (Rapid Collaborative Review REMDESIVIR FOR THE TREATMENT OF COVID-19 PICO AND EVIDENCE GAPS, https://eunethta.eu/ptrcr15/) of the European network of HTA agencies EUnetHTA were published, in which the HTA Department of the State Expert Center (the Center) of the Ministry of Health of Ukraine acted as an authorized reviewer.
The rapid collaborative review of the clinical effectiveness of the medicinal product remdesivir was aimed at determining, in accordance with the national requirements of the EUnetHTA partner countries, the PICO scheme (study population (patients), technology under study, alternative technology; treatment outcomes) and the gaps in the evidence base for the medicinal product remdesivir for the target group of patients with relevant comparators. The assessment working group consisted of authors – experts of the National Authority of Medicines and Health Products (INFARMED), Portugal; a co-author – experts of the National Centre for Pharmacoeconomics (NCPE), Ireland; and designated reviewers – experts of the Austrian Institute for HTA (AIHTA), Austria, the Emilia-Romagna Region (RER), Italy, and the HTA Department of the Center of the Ministry of Health of Ukraine.
For reference. In April 2019, the HTA Department was accepted as an associate member of EUnetHTA following the participation of the Director of the HTA Department O. B. Piniazhko in the General Assembly and forum in Amsterdam (10-11 April 2019) at the invitation of the organizing committee. EUnetHTA ensures cooperation between participating countries to implement best practices in HTA at the regional, European, and national levels. In addition to participating in the joint international assessment of the medicinal product remdesivir, experts of the HTA Department have already been involved in the assessment of the medicinal products brolucizumab and pretomanid. Currently, experts of the HTA Department are involved in the joint assessment of the clinical effectiveness of the medicinal product venetoclax.
